Neoplasms

All Conditions

Digestive System Diseases

Rare Diseases

Carcinoma

Carcinoma, Squamous Cell

Esophageal Neoplasms

Esophageal Squamous Cell Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Squamous Cell

Gastrointestinal Neoplasms

Digestive System Neoplasms

Head and Neck Neoplasms

Gastrointestinal Diseases

Esophageal Diseases

Esophageal Cancer

Antineoplastic Agents

All Drugs and Chemicals

Micronutrients

Hematinics

Vitamins

Raltitrexed

Antimetabolites

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Enzyme Inhibitors

Folinic Acid

Folate

Vitamin B9

Raltitrexed 2.6mg/m2 was administered on d1、d22

raltitrexed

Concurrent chemoradiotherapy is one of the curative options for esophageal squamous cell carcinoma. We evaluated the efficacy and toxicity of raltitrexed with concurrent radiotherapy in elderly patients with esophageal cancer.

Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus

Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus: A Phase-II Study

From the date of randomization until the date of death

From the date of randomization to the date of first observation of disease progression, or relapse, or death due to any cause

Toxicities were graded according to the National Cancer Institute Common Toxicity Criteria (NCICTC), version 3.0

QOL is respectively evaluated at randomization and 1 month, 3 month, 6 month and yearly after treatment among patients by using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C-30 (EORTC QLQ-C30)

Huai'an First People's Hospital

Docetaxel

Cisplatin

Tubulin Modulators

Antimitotic Agents

All patients in this group will receive concurrent chemoradiotherapy with DP regimen (docetaxel plus cisplatin).

All patients in this group will receive radiotherapy alone 50Gy (2.0 Gy/fraction, 5 days a week).

cisplatin 25mg/m2 on day 1 and docetaxel 25mg/m2 on day 1 weekly for 5 weeks

Docetaxel plus cisplatin

radiotherapy: 50Gy (2.0 Gy/fraction, 5 days a week)

radiotherapy

The aim of this study is to investigate the effect of postoperative concurrent chemoradiotherapy versus radiotherapy alone for patients with locally advanced esophageal squamous cell carcinoma.

Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma

A Randomized Phase Ⅱ/Ⅲ Trial of Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma

From the date of randomization to the date of first observation of disease progression, or relapse, or death due to any cause。

Quality of life of patient will be evaluated using EORTC QLQ-C30. Evaluation of quality of life will be performed every 3 months.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Raltitrexed Concurrent With Radiotherapy for Elderly Chinese Patients With Squamous Cell Carcinoma of Esophagus	NCT03585530	Esophagus Squam...	raltitrexed	70 Years - 85 Years	Huai'an First People's Hospital
Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma	NCT03600831	Esophageal Squa...	Docetaxel plus ... radiotherapy	18 Years - 70 Years	Huai'an First People's Hospital

Spots Global Cancer Trial Database for esophageal neoplasma